Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone

R. A. Evans; E. Hills; C. R. Dunstan; S. Y. P. Wong

doi:10.1111/j.1445-5994.1983.tb04658.x

Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone

R. A. Evans, E. Hills, C. R. Dunstan, S. Y. P. Wong

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

Ethane-l-hydroxy-l, l-diphosphonate (EHDP) 5 mg/kg body weight/day was administered to a patient suffering from Paget's disease of bone. After 150 days of treatment, when the plasma alkaline phosphatase was 40% of initial, he suffered a pathologic fracture of his Pagetic right patella, which was found to have osteomalacia of extreme severity. An iliac crest bone biopsy, following double tetracycline labels, also showed severe osteomalacia of Pagetic bone. Osteoclast acid phosphatase activity was reduced, as occurs in diphosphonate-treated rats. The patient's history included two previous pathologic fractures of Pagetic bone and unusual sensitivity to EHDP. It might be prudent to perform needle bone biopsy in order to exclude osteomalacia in EHDP-treated _ patients with these clinical manifestations.

Original language	English
Pages (from-to)	277-279
Number of pages	3
Journal	Australian and New Zealand Journal of Medicine
Volume	13
Issue number	3
DOIs	https://doi.org/10.1111/j.1445-5994.1983.tb04658.x
Publication status	Published - 1983

Access to Document

10.1111/j.1445-5994.1983.tb04658.x

Fingerprint Dive into the research topics of 'Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone'. Together they form a unique fingerprint.

Cite this

@article{4389bcc057c340c1bc333395ef9d3027,

title = "Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone",

abstract = "Ethane-l-hydroxy-l, l-diphosphonate (EHDP) 5 mg/kg body weight/day was administered to a patient suffering from Paget's disease of bone. After 150 days of treatment, when the plasma alkaline phosphatase was 40% of initial, he suffered a pathologic fracture of his Pagetic right patella, which was found to have osteomalacia of extreme severity. An iliac crest bone biopsy, following double tetracycline labels, also showed severe osteomalacia of Pagetic bone. Osteoclast acid phosphatase activity was reduced, as occurs in diphosphonate-treated rats. The patient's history included two previous pathologic fractures of Pagetic bone and unusual sensitivity to EHDP. It might be prudent to perform needle bone biopsy in order to exclude osteomalacia in EHDP-treated _ patients with these clinical manifestations.",

keywords = "Osteomalacia diphosphonates Paget's disease pathologic fracture bone",

author = "Evans, {R. A.} and E. Hills and Dunstan, {C. R.} and Wong, {S. Y. P.}",

year = "1983",

doi = "10.1111/j.1445-5994.1983.tb04658.x",

language = "English",

volume = "13",

pages = "277--279",

journal = "Australian and New Zealand Journal of Medicine",

issn = "1444-0903",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone

AU - Evans, R. A.

AU - Hills, E.

AU - Dunstan, C. R.

AU - Wong, S. Y. P.

PY - 1983

Y1 - 1983

N2 - Ethane-l-hydroxy-l, l-diphosphonate (EHDP) 5 mg/kg body weight/day was administered to a patient suffering from Paget's disease of bone. After 150 days of treatment, when the plasma alkaline phosphatase was 40% of initial, he suffered a pathologic fracture of his Pagetic right patella, which was found to have osteomalacia of extreme severity. An iliac crest bone biopsy, following double tetracycline labels, also showed severe osteomalacia of Pagetic bone. Osteoclast acid phosphatase activity was reduced, as occurs in diphosphonate-treated rats. The patient's history included two previous pathologic fractures of Pagetic bone and unusual sensitivity to EHDP. It might be prudent to perform needle bone biopsy in order to exclude osteomalacia in EHDP-treated _ patients with these clinical manifestations.

AB - Ethane-l-hydroxy-l, l-diphosphonate (EHDP) 5 mg/kg body weight/day was administered to a patient suffering from Paget's disease of bone. After 150 days of treatment, when the plasma alkaline phosphatase was 40% of initial, he suffered a pathologic fracture of his Pagetic right patella, which was found to have osteomalacia of extreme severity. An iliac crest bone biopsy, following double tetracycline labels, also showed severe osteomalacia of Pagetic bone. Osteoclast acid phosphatase activity was reduced, as occurs in diphosphonate-treated rats. The patient's history included two previous pathologic fractures of Pagetic bone and unusual sensitivity to EHDP. It might be prudent to perform needle bone biopsy in order to exclude osteomalacia in EHDP-treated _ patients with these clinical manifestations.

KW - Osteomalacia diphosphonates Paget's disease pathologic fracture bone

U2 - 10.1111/j.1445-5994.1983.tb04658.x

DO - 10.1111/j.1445-5994.1983.tb04658.x

M3 - Article

VL - 13

SP - 277

EP - 279

JO - Australian and New Zealand Journal of Medicine

JF - Australian and New Zealand Journal of Medicine

SN - 1444-0903

IS - 3

ER -